| Literature DB >> 29609557 |
Reena Thriumani1, Ammar Zakaria2, Yumi Zuhanis Has-Yun Hashim3,4, Amanina Iymia Jeffree5, Khaled Mohamed Helmy6, Latifah Munirah Kamarudin5, Mohammad Iqbal Omar5, Ali Yeon Md Shakaff5, Abdul Hamid Adom5, Krishna C Persaud7.
Abstract
BACKGROUND: Volatile organic compounds (VOCs) emitted from exhaled breath from human bodies have been proven to be a useful source of information for early lung cancer diagnosis. To date, there are still arguable information on the production and origin of significant VOCs of cancer cells. Thus, this study aims to conduct in-vitro experiments involving related cell lines to verify the capability of VOCs in providing information of the cells.Entities:
Keywords: E-nose; GCMS-SPME; In-vitro; Lung cancer; VOCs
Mesh:
Substances:
Year: 2018 PMID: 29609557 PMCID: PMC5879746 DOI: 10.1186/s12885-018-4235-7
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
List of sensor array used, cell lines, cell growth time considered for measurement (incubated period) and type of matrix used in in-vitro studies aiming to distinguish type of lung cancer by previous studies
| Sensor Type | Cell lines | Control | Incubation (hours) | Matrix Type | Statistical Approach | Reference |
|---|---|---|---|---|---|---|
| GNP | NSCLC: A549, Calu-3, H1650, | Pure medium | - | Culture medium with cells | PCA | [ |
| GNP | NSCLC: A549, Calu-3, H1650, H4006, H1435, H820, H1975, H2009, HCC95, HCC15, H226 and NE18 | IBE, pure medium | 68 | Culture medium with cells | Linear nu-SVC-SVM; cross validation | [ |
| C320 | NSCLC: L55, L65, A549, H460, M51 and REN | NHDF and HASM | - | Cells in saline solution | MD | [ |
List of sensor array used, cancer cell lines, cell growth time considered for measurement (incubated period) and type of matrix used in this work
| Sensor Type | Cell lines | Control | Incubations (hours) | Matrix Type | Statistical Approach |
|---|---|---|---|---|---|
| C320 | NSCLC: A459 and Calu-3 | WI38VA13, MCF7 and pure medium | 24, 48, 72 | Culture medium with cells |
Characteristic of the cell lines
| Cell Lines | Oncogene | Histology | Patient Type | Tissue Type | Growth Medium |
|---|---|---|---|---|---|
| A549 | K-Ras mutation | Adeno-carcinoma | Male, 58 years Caucasian | Lung (epithelial cell) | DMEM |
| Calu-3 | EGFR, K-Ras, TP53 and CDKNA genes mutation | Adeno-carcinoma | Male, 25 years, Caucasian | Lung (epithelial cell) from pleural effusion | EMEM |
| MCF-7 | WNT7B mutation | Adeno-carcinoma | Female, 68 years | Mammary gland (epithelial cell) from pleural effusion | DMEM |
| WI38VA13 | - | Normal cell | Female,Caucasian,3 months | Lung (Fibroblast) | DMEM |
Fig. 1The Cyranose 320 Setup for Data Collection: Snout of Cyranose 320 was inserted into the T-25cm2 flask containing cell cultures
Parameter settings of the Cyranose 320 for data collection procedure [85]
| Parameters | Time (s) | Pump Speed (cc/min) |
|---|---|---|
| Baseline Purge | 10 | 160 |
| Sample Draw | 180 | 120 |
| Snout Removal | 3 | - |
| 1stAir Intake Purge | 40 | 180 |
| Filter: ON | - | - |
The e-nose was set to be at 37°C (optimum temperature for culture growth)
Fig. 2Example of five complete cycles of the feature space extracted from sensor 12 of the e -nose using A549 sample at 24th hour
Fig. 3The block diagram of data analysis conducted using Cyranose 320
Fig. 4The GCMS-SPME odour sampling procedure. SPME coated needle was exposed to the headspace of cultured cell. The experiment was conducted in an incubator (37°C/5% CO2)
The Significant test using Wilk’s Lambda for LDA
| Test of Function(s) | Wilks' Lambda | Chi-square | df | Sig. |
|---|---|---|---|---|
| 1 through 5 | .000 | 8432.165 | 75 | .000 |
| 2 through 5 | .000 | 3116.215 | 56 | .000 |
| 3 through 5 | .033 | 1214.302 | 39 | .000 |
| 4 through 5 | .246 | 496.519 | 24 | .000 |
| 5 | .911 | 32.974 | 11 | .001 |
Df different function, Sig significant value
Fig. 5LDA plot of volatile compounds from cultured cells (combination of all 3 days). The separability of 4 types of cell lines and two different blank medium shows the effectiveness of the e-nose
Fig. 6a PCA plot of volatile compounds of cultured cells (combination of all 3 days). The separability of 4 types of cell lines and two different blank medium shows the effectiveness of the e-nose. b PCA plot of volatile compounds of lung cancer cultured cells (combination of all 3 days). The separability of 2 types of lung cancer cell lines shows the effectiveness of the e-nose
Performance rate of Fisher-Linear Discriminant Analysis
| Time (h) | Classes | Performance rate of LDA (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Train and Validate | Test | ||||||||||
| ACC | SEN | SPEC | PREC | MCC | ACC | SEN | SPEC | PREC | MCC | ||
| 24 | A549 | 90.86 | 98.41 | 98.93 | 98.41 | 0.91 | 96.89 | 98.61 | 98.88 | 98.44 | 0.94 |
| Calu3 | 94.84 | 94.38 | 95.50 | 98.52 | 0.75 | 95.15 | 95.26 | 96.18 | 97.52 | 0.74 | |
| MCF7 | 94.32 | 94.92 | 95.50 | 88.89 | 0.80 | 95.01 | 94.72 | 96.30 | 90.32 | 0.82 | |
| WI38VA13 | 94.73 | 93.20 | 95.72 | 92.86 | 0.89 | 95.56 | 94.50 | 94.53 | 92.99 | 0.89 | |
| DMEM | 93.25 | 93.33 | 95.18 | 87.69 | 0.75 | 92.96 | 92.63 | 95.75 | 93.17 | 0.78 | |
| EMEM | 90.22 | 92.25 | 91.33 | 84.39 | 0.70 | 90.96 | 89.84 | 95.65 | 83.01 | 0.67 | |
| 48 | A549 | 94.89 | 98.45 | 98.94 | 98.50 | 0.98 | 96.90 | 99.47 | 99.87 | 98.51 | 0.98 |
| Calu3 | 92.99 | 98.21 | 95.81 | 98.64 | 0.78 | 96.75 | 94.18 | 98.17 | 97.88 | 0.82 | |
| MCF7 | 95.32 | 96.86 | 95.78 | 90.38 | 0.85 | 96.51 | 91.30 | 97.64 | 95.45 | 0.90 | |
| WI38VA13 | 95.32 | 96.30 | 96.07 | 94.11 | 0.88 | 95.90 | 96.51 | 95.20 | 94.14 | 0.92 | |
| DMEM | 93.65 | 80.00 | 55.58 | 92.86 | 0.50 | 93.89 | 50.00 | 93.00 | 97.13 | 0.53 | |
| EMEM | 94.11 | 91.38 | 92.38 | 89.74 | 0.45 | 94.09 | 93.10 | 97.36 | 90.19 | 0.86 | |
| 72 | A549 | 94.91 | 98.62 | 98.97 | 98.50 | 0.98 | 96.92 | 99.54 | 99.89 | 98.63 | 0.96 |
| Calu3 | 94.04 | 98.67 | 94.52 | 98.34 | 0.86 | 97.41 | 95.33 | 98.04 | 97.71 | 0.85 | |
| MCF7 | 95.95 | 96.98 | 96.00 | 92.32 | 0.92 | 97.12 | 92.91 | 97.76 | 95.71 | 0.95 | |
| WI38VA13 | 95.59 | 97.05 | 96.57 | 94.23 | 0.93 | 96.34 | 96.54 | 97.30 | 94.70 | 0.88 | |
| DMEM | 93.52 | 83.08 | 96.00 | 94.30 | 0.65 | 93.68 | 52.31 | 93.21 | 97.25 | 0.71 | |
| EMEM | 94.44 | 88.89 | 94.80 | 73.85 | 0.52 | 91.85 | 88.89 | 95.21 | 90.75 | 0.37 | |
Performance rate of Naïve Bayes classifier
| Time (h) | Classes | Performance rate of NB (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Train and Validate | Test | ||||||||||
| ACC | SEN | SPEC | PREC | MCC | ACC | SEN | SPEC | PREC | MCC | ||
| 24 | A549 | 96.87 | 97.00 | 99.32 | 99.45 | 0.97 | 99.39 | 99.27 | 99.68 | 99.47 | 0.95 |
| Calu3 | 97.56 | 96.13 | 98.41 | 99.35 | 0.95 | 99.34 | 96.25 | 99.54 | 99.49 | 0.94 | |
| MCF7 | 98.70 | 97.44 | 97.68 | 95.79 | 0.93 | 99.23 | 98.31 | 99.29 | 90.63 | 0.84 | |
| WI38VA13 | 98.83 | 94.91 | 95.67 | 99.22 | 0.96 | 99.34 | 94.23 | 99.65 | 94.23 | 0.88 | |
| DMEM | 92.86 | 61.52 | 98.09 | 70.59 | 0.38 | 97.10 | 73.68 | 98.63 | 77.78 | 0.53 | |
| EMEM | 91.71 | 60.22 | 96.77 | 56.12 | 0.33 | 92.81 | 73.02 | 94.18 | 46.46 | 0.87 | |
| 48 | A549 | 99.93 | 97.00 | 99.92 | 98.80 | 0.98 | 99.96 | 97.35 | 99.94 | 99.93 | 0.94 |
| Calu3 | 96.72 | 97.48 | 99.54 | 83.00 | 0.47 | 96.27 | 97.18 | 98.74 | 79.63 | 0.52 | |
| MCF7 | 99.50 | 95.06 | 99.89 | 99.87 | 0.97 | 99.23 | 91.30 | 99.88 | 98.44 | 0.93 | |
| WI38VA13 | 99.33 | 95.81 | 99.61 | 93.59 | 0.87 | 99.12 | 94.52 | 99.52 | 94.52 | 0.89 | |
| DMEM | 93.72 | 84.80 | 97.11 | 64.29 | 0.74 | 93.58 | 85.52 | 98.57 | 60.91 | 0.77 | |
| EMEM | 98.60 | 83.96 | 99.45 | 91.95 | 0.81 | 99.01 | 88.28 | 99.06 | 87.69 | 0.79 | |
| 72 | A549 | 99.93 | 97.00 | 99.92 | 98.99 | 0.98 | 100.00 | 100.00 | 100.00 | 100.00 | 1.00 |
| Calu3 | 96.41 | 95.90 | 96.24 | 64.75 | 0.36 | 96.78 | 90.00 | 97.25 | 69.23 | 0.43 | |
| MCF7 | 99.75 | 97.00 | 100.00 | 100.00 | 1.00 | 100.00 | 100.00 | 100.00 | 100.00 | 1.00 | |
| WI38VA13 | 99.70 | 97.00 | 99.68 | 96.19 | 0.94 | 99.78 | 97.96 | 99.88 | 97.96 | 0.96 | |
| DMEM | 92.56 | 87.53 | 96.85 | 91.75 | 0.66 | 93.19 | 80.00 | 97.01 | 91.23 | 0.67 | |
| EMEM | 97.25 | 90.75 | 97.51 | 73.77 | 0.59 | 98.47 | 94.44 | 98.73 | 82.26 | 0.69 | |
Performance rate of K-Nearest Neighbour classifier
| Time (h) | Classes | Performance rate of KNN (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Train and Validate | Test | ||||||||||
| ACC | SEN | SPEC | PREC | MCC | ACC | SEN | SPEC | PREC | MCC | ||
| 24 | A549 | 99.08 | 97.67 | 99.17 | 99.50 | 0.91 | 99.47 | 97.97 | 99.20 | 99.60 | 0.91 |
| Calu3 | 99.87 | 99.98 | 99.86 | 97.75 | 0.96 | 92.70 | 99.84 | 99.07 | 99.57 | 0.98 | |
| MCF7 | 99.01 | 99.77 | 99.54 | 99.65 | 0.97 | 99.04 | 99.87 | 99.92 | 99.80 | 0.97 | |
| WI38VA13 | 99.41 | 99.48 | 99.37 | 99.33 | 0.95 | 98.80 | 99.40 | 98.80 | 92.30 | 0.89 | |
| DMEM | 99.54 | 92.47 | 97.32 | 96.35 | 0.92 | 93.80 | 87.50 | 97.38 | 96.45 | 0.94 | |
| EMEM | 99.93 | 98.85 | 96.37 | 91.02 | 0.88 | 87.10 | 71.40 | 98.40 | 85.20 | 0.92 | |
| 48 | A549 | 99.89 | 99.01 | 99.78 | 96.39 | 0.94 | 99.00 | 99.23 | 99.81 | 96.85 | 0.95 |
| Calu3 | 99.60 | 98.81 | 99.65 | 94.32 | 0.91 | 99.71 | 99.05 | 99.50 | 94.29 | 0.93 | |
| MCF7 | 99.87 | 98.02 | 100.00 | 100.00 | 0.99 | 100.00 | 100.00 | 100.00 | 100.00 | 1.00 | |
| WI38VA13 | 99.86 | 97.47 | 100.00 | 95.62 | 0.95 | 99.37 | 99.59 | 99.60 | 95.36 | 0.94 | |
| DMEM | 94.73 | 58.67 | 96.51 | 45.36 | 0.32 | 92.20 | 50.80 | 96.10 | 54.10 | 0.39 | |
| EMEM | 94.53 | 89.02 | 97.86 | 80.98 | 0.79 | 93.70 | 97.20 | 97.00 | 89.00 | 0.72 | |
| 72 | A549 | 99.94 | 98.98 | 99.93 | 98.98 | 0.93 | 99.90 | 99.89 | 99.83 | 99.93 | 0.96 |
| Calu3 | 99.60 | 96.41 | 98.98 | 98.79 | 0.96 | 99.75 | 99.58 | 99.55 | 95.20 | 0.95 | |
| MCF7 | 100.00 | 100.00 | 100.00 | 100.00 | 1.00 | 100.00 | 100.00 | 100.00 | 100.00 | 1.00 | |
| WI38VA13 | 100.00 | 100.00 | 100.00 | 100.00 | 1.00 | 99.80 | 99.67 | 100.00 | 100.00 | 0.97 | |
| DMEM | 96.46 | 78.04 | 95.72 | 86.34 | 0.63 | 86.80 | 100.00 | 85.80 | 86.36 | 0.66 | |
| EMEM | 99.60 | 100.00 | 99.58 | 94.12 | 0.91 | 94.20 | 18.50 | 100.00 | 100.00 | 0.40 | |
Performance rate of Probabilistic Neural Network classifier
| Time (h) | Classes | Performance rate of PNN (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Train and Validate | Test | ||||||||||
| ACC | SEN | SPEC | PREC | MCC | ACC | SEN | SPEC | PREC | MCC | ||
| 24 | A549 | 99.62 | 98.77 | 99.22 | 99.59 | 0.92 | 99.65 | 99.08 | 99.39 | 99.69 | 0.94 |
| Calu3 | 99.89 | 99.98 | 99.89 | 98.05 | 0.97 | 99.87 | 99.89 | 98.70 | 98.91 | 0.96 | |
| MCF7 | 99.11 | 99.80 | 99.58 | 99.69 | 0.98 | 99.04 | 99.87 | 99.92 | 99.80 | 0.97 | |
| WI38VA13 | 99.50 | 99.57 | 99.43 | 99.44 | 0.94 | 99.61 | 99.62 | 99.47 | 99.49 | 0.96 | |
| DMEM | 99.57 | 95.97 | 99.31 | 97.33 | 0.93 | 99.80 | 95.99 | 99.48 | 97.75 | 0.95 | |
| EMEM | 99.90 | 98.93 | 96.47 | 91.02 | 0.89 | 99.93 | 97.14 | 95.14 | 91.22 | 0.89 | |
| 48 | A549 | 99.91 | 99.75 | 99.93 | 98.80 | 0.97 | 99.90 | 98.51 | 97.02 | 98.87 | 0.96 |
| Calu3 | 99.93 | 98.93 | 99.75 | 99.86 | 0.98 | 99.94 | 98.51 | 100.00 | 100.00 | 0.99 | |
| MCF7 | 99.90 | 96.43 | 99.86 | 97.59 | 0.94 | 99.95 | 97.00 | 99.92 | 98.57 | 0.95 | |
| WI38VA13 | 99.90 | 98.00 | 100.00 | 100.00 | 1.00 | 100.00 | 100.00 | 100.00 | 100.00 | 1.00 | |
| DMEM | 95.24 | 94.43 | 94.93 | 96.67 | 0.92 | 91.57 | 81.03 | 95.05 | 62.47 | 0.79 | |
| EMEM | 96.93 | 98.22 | 98.66 | 90.87 | 0.82 | 96.97 | 98.36 | 98.78 | 92.39 | 0.84 | |
| 72 | A549 | 99.93 | 100.00 | 99.93 | 98.99 | 0.97 | 100.00 | 100.00 | 100.00 | 100.00 | 1.00 |
| Calu3 | 99.94 | 98.90 | 100.00 | 100.00 | 0.99 | 99.69 | 100.00 | 99.67 | 95.24 | 0.93 | |
| MCF7 | 99.92 | 97.00 | 99.91 | 97.73 | 0.93 | 99.97 | 97.54 | 99.68 | 94.23 | 0.92 | |
| WI38VA13 | 100.00 | 100.00 | 100.00 | 100.00 | 1.00 | 100.00 | 100.00 | 100.00 | 100.00 | 1.00 | |
| DMEM | 91.24 | 94.41 | 95.80 | 88.11 | 0.70 | 91.66 | 94.62 | 96.01 | 88.57 | 0.68 | |
| EMEM | 97.73 | 58.53 | 98.90 | 94.82 | 0.67 | 97.99 | 58.99 | 98.97 | 95.63 | 0.69 | |
Performance rate of Support Vector Machine classifier
| Time (h) | Classes | Performance rate of SVM (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Train and Validate | Test | ||||||||||
| ACC | SEN | SPEC | PREC | MCC | ACC | SEN | SPEC | PREC | MCC | ||
| 24 | A549 | 99.69 | 99.24 | 99.93 | 99.67 | 0.98 | 99.86 | 99.65 | 99.96 | 99.82 | 0.98 |
| Calu3 | 99.93 | 99.81 | 99.92 | 99.89 | 0.98 | 99.84 | 99.87 | 99.72 | 99.76 | 0.98 | |
| MCF7 | 99.98 | 99.87 | 99.97 | 99.92 | 0.96 | 99.94 | 99.95 | 99.98 | 99.89 | 0.98 | |
| WI38VA13 | 99.72 | 99.80 | 99.72 | 99.84 | 0.97 | 99.71 | 99.82 | 99.83 | 99.87 | 0.97 | |
| DMEM | 99.46 | 96.77 | 99.65 | 98.32 | 0.94 | 99.85 | 96.99 | 99.69 | 98.75 | 0.96 | |
| EMEM | 99.86 | 100.00 | 99.85 | 97.75 | 0.97 | 96.38 | 96.19 | 97.83 | 91.64 | 0.87 | |
| 48 | A549 | 99.82 | 99.72 | 99.94 | 99.30 | 0.97 | 99.97 | 99.79 | 99.97 | 99.76 | 0.97 |
| Calu3 | 99.79 | 99.70 | 100.00 | 100.00 | 0.98 | 99.47 | 99.64 | 99.88 | 99.89 | 0.98 | |
| MCF7 | 99.99 | 99.45 | 100.00 | 100.00 | 0.99 | 100.00 | 100.00 | 100.00 | 100.00 | 1.00 | |
| WI38VA13 | 99.86 | 99.89 | 100.00 | 100.00 | 0.99 | 100.00 | 100.00 | 100.00 | 100.00 | 1.00 | |
| DMEM | 97.52 | 97.83 | 97.49 | 92.00 | 0.81 | 92.62 | 76.07 | 94.55 | 41.86 | 0.78 | |
| EMEM | 100.00 | 100.00 | 100.00 | 100.00 | 1.00 | 99.12 | 100.00 | 99.06 | 87.88 | 0.80 | |
| 72 | A549 | 99.98 | 99.71 | 99.93 | 99.82 | 0.90 | 100.00 | 100.00 | 100.00 | 100.00 | 1.00 |
| Calu3 | 100.00 | 100.00 | 100.00 | 100.00 | 1.00 | 99.96 | 99.93 | 99.88 | 99.83 | 0.98 | |
| MCF7 | 100.00 | 100.00 | 100.00 | 100.00 | 1.00 | 100.00 | 100.00 | 100.00 | 100.00 | 1.00 | |
| WI38VA13 | 99.64 | 80.20 | 100.00 | 100.00 | 0.89 | 100.00 | 100.00 | 100.00 | 100.00 | 1.00 | |
| DMEM | 97.52 | 88.82 | 99.86 | 96.15 | 0.71 | 95.36 | 82.31 | 100.00 | 100.00 | 0.85 | |
| EMEM | 97.84 | 100.00 | 91.31 | 82.67 | 0.81 | 95.76 | 81.85 | 98.43 | 86.67 | 0.84 | |
Compounds detected from the headspace of in vitro cultured cell lines (>80% of the NIST matching percentage)
| Retention Time (min) | Library/ID | Summary of All Substances Identified by Spectral Match | CAS number | |||||
|---|---|---|---|---|---|---|---|---|
| A549 | Calu-3 | MCF7 | WI38VA13 | DMEM | EMEM | |||
| 3.33 | Amphetamine | - | - | - | + | - | - | 300-62-9 |
| 3.44 | Decane | + | + | + | - | - | - | 124-18-5 |
| 4.25 | Ethylbenzene | + | + | + | + | + | - | 100-41-4 |
| 4.95 | O-Xylene | - | - | - | + | - | - | 95-47-6 |
| 5.30 | Propylbenzene | + | + | + | + | + | - | 103-65-1 |
| 5.51 | 1-Ethyl-2-methylbenzene | + | + | + | + | - | - | 611-14-3 |
| 5.74 | Styrene | + | ++ | ++ | ++ | ++ | - | 100-42-5 |
| 6.18 | Dodecane | - | + | + | - | - | - | 112-40-3 |
| 6.28 | 1,2,4-Trimethyl-benzene | - | - | - | + | - | - | 95-63-6 |
| 6.57 | Trimethyl[4(trimethylsilyl)butoxy]silane | + | + | + | + | + | - | 7140-91-2 |
| 7.52 | Cyclohexanol | + | + | + | + | + | - | 108-93-097 |
| 7.64 | Decanal | + | - | - | - | - | - | 112-31-2 |
| 7.68 | Nonanal | + | - | - | + | - | - | 124-19-6 |
| 7.69 | 3,4-Dimethylheptane | - | - | + | - | - | - | 922-28-1 |
| 8.02 | 2,4-DimethylUndecane | - | - | - | + | - | - | 17312-80-0 |
| 8.33 | 1,3-Bis(1,1-dimethylethyl)benzene | + | + | + | + | + | - | 1014-60-4 |
| 8.67 | Tetradecane | + | - | + | + | + | - | 629-59-4 |
| 8.74 | 2-Ethyldodecanol | - | + | - | - | - | - | 19780-33-7 |
| 8.75 | 2-Ethylhexanol | - | + | - | + | - | - | 104-76-7 |
| 9.00 | Benzaldehyde | + | - | + | + | + | - | 100-52-7 |
| 10.25 | Dimethylsilanediol | + | + | + | + | + | + | 1066-42-8 |
| 10.55 | Acetophenone | + | - | + | + | + | - | 98-86-2 |
| 10.60 | Ethanedioic acid, bis(trimethylsilyl)ester | + | + | + | + | + | - | 18294-04-7 |
| 10.88 | 2-Ethyl-1,3-dimethyl-benzene | - | + | + | - | - | - | 2870-04-4 |
| 10.92 | 1-Methyl-2-Pyrrolidinone | + | - | + | - | + | - | 872-50-4 |
| 11.30 | Heptadecane | - | - | - | + | - | - | 629-78-7 |
| 11.22 | Heneicosane | + | + | - | - | - | - | 629-94-7 |
| 11.30 | Hexadecane | - | - | + | - | - | - | 544-76-3 |
| 11.37 | 2-(Aminooxy)-Propanoic acid | - | - | - | - | - | + | 2786-22-3 |
| 11.48 | 3-Methyl-3-Hexanol | - | - | - | - | - | + | 597-96-6 |
| 11.55 | Methoxyphenyl_Oxime | + | + | + | + | + | + | 1000222-86-6 |
| 12.96 | 2-Phenyl-2-Butanone | - | - | + | - | - | - | 2550-26-7-97 |
++: Percentage of peak area more than 50%; +: percentage of peak area less than 50%; - : not detected (peak area < 1%)
VOCs discriminating the headspace of lung cancer cell lines and blank mediums. Analysis of abundances of VOCS in the headspace of lung cancer cell lines using GCMS-SPME. VOCs increased (emitted) and or decreases (consumed) by lung cancer are reported with respect to blank medium. A p-value < 0.05 has been considered statistically significant
| Trend | Library/ID | |
|---|---|---|
| Increase | Decane | 1.50E-5 |
| Ethylbenzene | 0.052 | |
| Propylbenzene | 0.011 | |
| 1-Ethyl-2-methylbenzene | 0.037 | |
| Styrene | 0.135 | |
| Dodecane | 0.033 | |
| Cyclohexanol | 0.102 | |
| Decanal | 0.001 | |
| Nonanal | 0.002 | |
| 1,3-Bis(1,1-dimethylethyl)benzene | 0.084 | |
| Tetradecane | 0.506 | |
| 2-Ethyldodecanol | 3.88E-5 | |
| 2-Ethylhexanol | 3.52E-5 | |
| Benzaldehyde | 0.590 | |
| Acetophenone | 0.750 | |
| 2-Ethyl-1,3-dimethyl-benzene | 0.036 | |
| 1-Methyl-2-Pyrrolidinone | 0.319 | |
| Heneicosane | 3.35E-6 | |
| Decrease | Trimethyl[4(trimethylsilyl)butoxy]silane | 0.101 |
| Ethanedioic acid, bis(trimethylsilyl)ester | 0.107 |
VOCs discriminating the headspace of lung cancer cell lines and control cell lines. Analysis of abundances of VOCS in the headspace of lung cancer, breast cancer and normal lung cell lines using GCMS-SPME. A p-value < 0.05 has been considered statistically significant
| Compounds | |||||
|---|---|---|---|---|---|
| A549/Calu3 | A549/MCF7 | A549/WI38VA13 | Calu3/MCF7 | Calu3/WI38VA13 | |
| Decane | 0.326 (↑) | 0.154 (↑) | 1.04E-4 (↑) | 0.127 (↓) | 0.016 (↑) |
| Propylbenzene | 0.507 (↑) | 0.533 (↑) | 0.104 (↓) | 0.988 (↓) | 0.071 (↓) |
| Dodecane | 1.67E-6 (↓) | 2.23E-5 (↓) | - | 0.011 (↑) | 1.67E-6 (↑) |
| Decanal | 0.001 (↑) | 0.001 (↑) | 0.001 (↑) | - | - |
| Nonanal | 0.002 (↑) | 0.002 (↑) | 1.17E-4 (↓) | - | 2.21E-4 (↓) |
| 3, 4-Dimethylheptane | - | 2.75E-4 (↓) | - | 2.75E-4 (↓) | - |
| 2, 4-DimethylUndecane | - | - | 0.017 (↓) | 0.017 (↓) | - |
| 2-Ethyldodecanol | 3.88E-5 (↓) | - | - | 3.88E-5 (↑) | 3.88E-5 (↑) |
| 2-Ethylhexanol | 3.53E-5 (↓) | - | 2.47E-7 (↓) | 3.53E-5 (↑) | 9.40E-5 (↑) |
| Heneicosane | 0.334 (↓) | 0.002 (↑) | 0.002 (↑) | 3.40E-4 (↑) | 3.40E-4 (↑) |
The (↑) and (↓) shows the trend of abundances increases and decreases in lung cancer cell line samples respectively
The potential lung cancer biomarkers detected in this study were compared to the in-vitro and in vivo results of previous studies which were found in Scopus database
| Class Specific compounds | Origin | Comparison with Literature | ||||
|---|---|---|---|---|---|---|
| Cell lines | aTissues | Breath | References | |||
| Alkanes Straight chain | Dodecane | Endogenous- lipid peroxidation by reactive oxygen species (ROS) s | ✓ | ✓ | ✓✓ | [ |
| - | ✓ | ✓ | [ | |||
| - | - | ✓ | [ | |||
| Aldehydes | Decanal | Endogenous- peroxidation of omega3 and omega6 fatty acids (PUFAs), components of cell membrane phospholipids | ✓ | ✓ | - | [ |
| Nonanal | ||||||
| Alcohol | 2-Ethyldodecanol | Endogenous- Hydroxylation of the lipid peroxidation biomarkers via cytochrome p450 enzymes | - | - | - | [ |
aPatient’s tissue
✓Compounds that were detected as lung cancer biomarkers in previous studies
- Compounds that have not been detected in the previous study